BioTime, Inc.  

(Public, NYSEMKT:BTX)   Watch this stock  
Find more results for NYSEAMEX:BTX
0.00 (0.00%)
May 21 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range     -
52 week 2.29 - 5.95
Open     -
Vol / Avg. 0.00/401,151.00
Mkt cap 381.36M
P/E     -
Div/yield     -
EPS -0.52
Shares 83.27M
Beta 0.96
Inst. own 37%
Aug 10, 2015
Q2 2015 BioTime Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 1, 2015
BioTime, Inc. at Jefferies 2015 Healthcare Conference Add to calendar
May 11, 2015
Q1 2015 BioTime Inc Earnings Release
Mar 11, 2015
Q4 2014 BioTime Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -995.69% -834.97%
Operating margin -1067.82% -966.63%
EBITD margin - -806.23%
Return on average assets -69.84% -66.02%
Return on average equity -146.41% -152.85%
Employees 117 -
CDP Score - -


1301 Harbor Bay Pkwy
ALAMEDA, CA 94502-2215
United States - Map
+1-510-5213390 (Phone)
+1-510-5213389 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioTime, Inc. is a biotechnology company. The Company is focused on the field of regenerative medicine; human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine is designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body. The field of regenerative medicine includes a range of disciplines, including tissue banking, cellular therapy, gene therapy and tissue engineering. Through its ESI BIO division, the Company offers human stem cell products and technologies that can be used by researchers at universities and at companies in the bioscience and biopharmaceutical industries. The Company has developed research and clinical grade hES cell lines. The Company’s subsidiary, ES Cell International Pte Ltd (ESI), has developed six hES cell lines.

Officers and directors

Alfred D. Kingsley Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Michael D. West Ph.D. Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Robert W. Peabody CPA Chief Financial Officer, Senior Vice President,
Age: 59
Bio & Compensation  - Reuters
Adi Mohanty Chief Operating Officer
Bio & Compensation  - Reuters
Judith Segall Vice President - Administration, Corporate Secretary, Director
Age: 60
Bio & Compensation  - Reuters
Michael H. Mulroy Director
Age: 48
Bio & Compensation  - Reuters
Angus C. Russell Director
Age: 59
Bio & Compensation  - Reuters
Deborah J. Andrews Independent Director
Age: 56
Bio & Compensation  - Reuters
Neal C. Bradsher Independent Director
Age: 48
Bio & Compensation  - Reuters
Stephen C. Farrell CPA Independent Director
Age: 49
Bio & Compensation  - Reuters